The role of particular adaptor proteins, such as CRK-I and CRK-II, in neoplastic development in a number of malignancies, has been established, but their involvement in bladder cancer has not been clarified. To investigate the potential role of these adaptor proteins in invasive bladder cancer, Matsumoto and coworkers used a cell culture and mouse xenograft system and investigated several key processes in malignant transformation, including cell proliferation and epithelial-mesenchymal transition. Here, the authors describe their findings that experimental reduction in the CRK adaptor proteins leads to decreased cell proliferation and reduced metastatic cells. These exciting findings suggest CRK as a potential target for future systemic agents aimed at treating human bladder cancers. doi: 10.1111/cas.12662 Persistent activation of STAT3 by PIM2-driven positive feedback loop for epithelial-mesenchymal transition in breast cancer Page 718-25
Breast cancer is one of the leading causes of cancer-related death in women worldwide. Although treatments for metastatic breast cancer have improved significantly over recent years, the disease continues to carry a grim overall prognosis. To better understand the process of epithelial-mesenchymal transition, which is a key step in the development of metastatic potential, Uddin et al. transfected cancer cells with siRNA to knock down molecules hypothesized to play a role in EMT. Through a technically challenging series of experiments, the authors identified several cytokine-dependent components of an intracellular signaling cascade that are required for EMT. By further elucidating this complex array of signaling molecules, the researchers open new avenues for targeted therapy in breast cancer treatment and potentially for chemoprotection against the development of metastatic disease. doi: 10.1111/cas.12668
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Breast cancer remains the most common cancer in women and human epidermal growth factor receptor-2 (Her-2)-positive breast cancer makes up approximately 25% of this population. Her-2 positive breast cancer is particularly dangerous as it confers worse overall survival than Her-2-negative breast cancer, due to it being refractory to standard treatments. In this study, breast cancer tissue from 389 patients was compared with normal breast tissue (n = 117) for differences in ribosome-binding protein 1 (RRBP1) expression. What Liang et al. found was that expression of RRBP1 in Her-2-positive breast cancer samples significantly correlated with lower overall survival and lymph node metastasis. This study is important in setting the groundwork for future work into the pathophysiology of RBP1 and, potentially, its therapeutic value as a target for pharmacotherapy. doi: 10.1111/cas.12666
